SAT0117 Retention Rates of Adalimumab, Etanercept, and Infliximab as 1st- Or 2nd-Line Biotherapy for Rheumatoid Arthritis Patients in Daily Practice in Auvergne
doi 10.1136/annrheumdis-2017-eular.3676
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2017
Authors
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism